Abstract 1152
Background
This study was carried out as randomized-controlled, longitudinal interventional to determine whether there was a difference between the mean scores of compassion fatigue (CF), burnout (BO), compassion satisfaction (CS), perceived stress (PS) and psychological resilience (PR) after applying the short-term and long-term ‘Compassion Fatigue Resiliency Program’ for nurses working in the field of oncology-hematology.
Methods
The sample of the study consisted of oncology-hematology nurses working in two private hospitals, one university hospital. Hospitals were randomly assigned to experiment I (n:34), experiment II (n: 49) and control groups (n: 42). Short-term (two days, five hours per day) program implemented to experiment I, long-term (five weeks, 2 hours a week) program implemented to experiment II and no any intervention implemented to control group. Measurements were made pre-intervention, post-intervention, third month, sixth month and first year. The data were collected by personal information form, professional quality of life scale-IV, PS scale, and PR scale for adults. SPSS 24 package program was used to analyze the data of the study. Primary research hypotheses were tested with multilevel models (MLM).
Results
There was no statistically significant difference between the mean scores of CF, BO, PS and PR of the nurses in the short-term, long-term and control groups. The mean compassion satisfaction score of the nurses in the short-term and long-term education group was statistically significantly higher than in the control group. The mean CS scores of the nurses in both the short and long-term education groups were statistically significantly higher in the sixth month and first year follow-up measurements than in the pre-intervention period.
Conclusions
In this study, considering the effects of long-term and short-term education on CF, BO, CS, perceived stress and PR of nurses, it can be said that these two educations have the same effect on CS. It is the first study with randomized-controlled method, including the follow-up of up to a year. Doing new studies that are revealing the effect of this education can be suggested.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tuğba Pehlivan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract